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gest that cell transplantation has great potential, but
the mechanism of benefit remains incompletely char-
acterized. Histologic studies suggest that the engraft-
ed cells induce angiogenesis. The cells orient against
the cardiac stress and prevent thinning and dilatation
of the injured region. Careful sonometric studies per-
formed at Duke University suggest that engrafted
skeletal myoblasts altered the elasticity of the scarred
region.3 The altered elastic properties of the engraft-
ed region and the angiogenesis that is induced may
have prevented cardiac remodeling, avoiding cardiac
thinning and dilatation and congestive heart failure.
The benefits of cell transplantation have been shown
without demonstrating that the implanted cells beat
synchronously with the native heart. Heart cells
implanted into normal myocardium have been shown to
communicate with native cardiomyocytes by intercalat-
ed disks,6 but heart cells implanted into an infarct
region have not been shown to communicate with the
recipient cardiomyocytes.2 Skeletal myocytes implant-
ed into an infarct region appear to adopt a cardiac
cell–like morphology, but electrochemical connections
permitting synchronous contractility have not been
demonstrated.7 Smooth muscle cells proliferate and
hypertrophy in response to the stress of cardiac con-
tractions, but do not beat.4 Mesenchymal stem cells
derived from adult bone marrow can differentiate
toward a cardiac phenotype and have been induced to
beat synchronously in vitro.8 These cells communicate
with the normal cardiomyocytes by intercalated disks.
However, mesenchymal cells implanted in an infarct
region did not beat synchronously with the heart.9
Future studies should establish whether the implanted
cells assume a cardiac morphology, whether they com-
municate with the normal myocardium, and whether
they beat synchronously with the heart. Sonomicro-
metry permits an excellent assessment of regional
dimensions and thickening, but sonomicrometry cannot
differentiate implanted from hibernating native cells in
the infarct region. We used 99m technetium-Sestambi
single-photon emission tomography to evaluate perfu-
sion and wall motion in the infarct zone. Echo-
cardiography offers the hope of detecting synchronous
contraction of the transplanted cells. 
In this issue of the Journal, Rajnoch and colleagues10
present an interesting study of skeletal myoblast implan-
tation after cardiac injury. Their study suggests that
satellite cell implantation improved both regional and
global function. In most animal models used to evaluate
T he results of the first clinical experience with celltransplantation were reported to the American Heart
Association in November 2000 by Menasche and asso-
ciates1 of Paris. A 72-year-old man who had a trans-
mural myocardial infarction with an ejection fraction of
21% received skeletal myoblasts implanted into the
infarct region at the time of coronary bypass surgery.
Five months later, he had recovered from the operation,
and perfusion and function of the infarct region had
improved, perhaps related to the cell transplantation.
This initial case report provides hope that the damage
from an extensive myocardial infarction may be
reversed. Coronary bypass surgery is frequently inade-
quate to restore function in patients who have few
viable surviving myocytes in the infarct region. Cell
transplantation offers the promise of restoring function
in these unfortunate patients.2-4 However, the era of cell
transplantation has only begun. Major questions re-
main. What type of cell is appropriate for autotrans-
plantation? When should these cells be delivered and by
what route? What is the efficacy of cell transplantation
relative to other medical and surgical treatments? What
outcome measures can be used to compare alternative
treatments in blinded randomized trials?
A number of research groups have implanted heart
cells,2 skeletal muscle cells,3 smooth muscle cells,4
and bone marrow stem cells5 into injured myocardi-
um. The implanted cells engrafted within the injured
region and improved regional perfusion, wall thicken-
ing, and wall motion, as well as global function. The
animal studies and the initial clinical experience sug-
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cell transplantation, cardiac injury is induced either by
coronary ligation or by cryoinjury resulting in car-
diomyocyte loss and remodeling of the infarct region.
Remodeling has been uniformly associated with thin-
ning and dilatation of the infarct region and deteriora-
tion of global function. In the sheep model used in this
study, the myocardium was injured by intramyocardial
injection of a snake cardiotoxin. Unfortunately, the
sequence of events after the injection of the toxin was
not well documented in the control group. In some con-
trol animals, the injured region thinned and the heart
dilated. In the transplant group, the heart did not dilate
and global function did not deteriorate. However, a
blinded comparison between control and transplant ani-
mals is necessary to accurately conclude that cell trans-
plantation improved global or regional function. 
Regional ventricular function is extremely difficult to
assess. The authors of this study used color kinesis
echocardiography, which tracks regional movement.
Unfortunately, cardiac motion may alter the echo region
interrogated, and changes in preload, afterload, and ven-
tricular shape and size can influence the measurements.
These variables may have differed between control and
treatment animals. Therefore, the authors have not con-
vincingly demonstrated a difference in regional contrac-
tility, although their results are suggestive.
In summary, cell transplantation offers the promise of
restoring regional function for patients who have had
an extensive myocardial infarction. The recent report
from Paris demonstrates the clinical feasibility of this
new surgical technique. Future studies will need to
establish the relative efficacy of this approach.
Carefully conducted clinical trials using sensitive and
specific end points may help us to determine the rela-
tive value of cell transplantation.
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